125 Shares in The Cigna Group (NYSE:CI) Purchased by Pineridge Advisors LLC

Pineridge Advisors LLC purchased a new position in shares of The Cigna Group (NYSE:CI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 125 shares of the health services provider’s stock, valued at approximately $37,000.

Several other large investors have also recently added to or reduced their stakes in CI. FMR LLC grew its stake in shares of The Cigna Group by 13.8% during the 3rd quarter. FMR LLC now owns 15,967,363 shares of the health services provider’s stock valued at $4,567,783,000 after buying an additional 1,939,554 shares during the period. Sanders Capital LLC boosted its holdings in The Cigna Group by 1.3% in the fourth quarter. Sanders Capital LLC now owns 7,727,729 shares of the health services provider’s stock valued at $2,314,068,000 after acquiring an additional 97,277 shares during the last quarter. Morgan Stanley grew its position in The Cigna Group by 4.7% during the third quarter. Morgan Stanley now owns 4,973,106 shares of the health services provider’s stock valued at $1,422,657,000 after acquiring an additional 225,115 shares during the period. Norges Bank acquired a new stake in The Cigna Group during the fourth quarter worth about $1,006,348,000. Finally, Northern Trust Corp raised its holdings in shares of The Cigna Group by 5.9% in the 3rd quarter. Northern Trust Corp now owns 3,244,157 shares of the health services provider’s stock worth $928,056,000 after purchasing an additional 181,385 shares during the period. 86.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Hoeltzel Mary T. Agoglia sold 5,946 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $348.71, for a total value of $2,073,429.66. Following the sale, the senior vice president now owns 2,595 shares of the company’s stock, valued at approximately $904,902.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO David Cordani sold 31,209 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $355.17, for a total transaction of $11,084,500.53. Following the completion of the sale, the chief executive officer now owns 348,054 shares in the company, valued at approximately $123,618,339.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Hoeltzel Mary T. Agoglia sold 5,946 shares of The Cigna Group stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $348.71, for a total value of $2,073,429.66. Following the completion of the transaction, the senior vice president now owns 2,595 shares in the company, valued at $904,902.45. The disclosure for this sale can be found here. Insiders sold 55,193 shares of company stock worth $19,475,326 over the last three months. Corporate insiders own 0.60% of the company’s stock.

The Cigna Group Stock Performance

Shares of CI traded down $0.86 during midday trading on Friday, hitting $333.29. 907,518 shares of the stock traded hands, compared to its average volume of 1,606,879. The business’s 50 day moving average price is $344.30 and its two-hundred day moving average price is $328.13. The firm has a market capitalization of $94.68 billion, a PE ratio of 27.37, a price-to-earnings-growth ratio of 1.02 and a beta of 0.53. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.71 and a current ratio of 0.71. The Cigna Group has a 1-year low of $253.95 and a 1-year high of $365.71.

The Cigna Group (NYSE:CI) last issued its quarterly earnings data on Thursday, May 2nd. The health services provider reported $6.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.17 by $0.30. The Cigna Group had a return on equity of 17.24% and a net margin of 1.76%. The business had revenue of $57.25 billion during the quarter, compared to the consensus estimate of $56.59 billion. During the same period in the previous year, the firm posted $5.41 earnings per share. The business’s revenue was up 23.2% on a year-over-year basis. Equities research analysts predict that The Cigna Group will post 28.47 EPS for the current fiscal year.

The Cigna Group Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 20th. Stockholders of record on Tuesday, June 4th will be paid a $1.40 dividend. This represents a $5.60 dividend on an annualized basis and a dividend yield of 1.68%. The ex-dividend date is Tuesday, June 4th. The Cigna Group’s dividend payout ratio is currently 45.98%.

Analysts Set New Price Targets

CI has been the topic of a number of research reports. Baird R W raised shares of The Cigna Group to a “strong-buy” rating in a research note on Thursday, May 30th. Cantor Fitzgerald restated an “overweight” rating and set a $400.00 price objective on shares of The Cigna Group in a research note on Wednesday. StockNews.com lowered The Cigna Group from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Oppenheimer boosted their price target on The Cigna Group from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of The Cigna Group from $432.00 to $435.00 and gave the company an “overweight” rating in a research report on Thursday, May 30th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $373.87.

The Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.